Loren Data's SAM Daily™

FBO DAILY ISSUE OF SEPTEMBER 27, 2006 FBO #1766
SOLICITATION NOTICE

A -- Type 1 Diabetes Mouse Resource

Notice Date

5/3/2006
 

Notice Type

Solicitation Notice
 

NAICS

541710 — Research and Development in the Physical, Engineering, and Life Sciences
 

Contracting Office

Department of Health and Human Services, National Institutes of Health, Nat'l Institute of Diabetes, Digestive, & Kidney Diseases, 2 Democracy Plaza, Suite 700W 6707 Democracy Blvd., MSC 5455, Bethesda, MD, 20892-5455
 

ZIP Code

20892-5455
 

Solicitation Number

NIH-NIDDK-06-04
 

Response Due

7/7/2006
 

Point of Contact

Dana Harris, Contract Specialist, Phone 301-594-9987, Fax 301-480-4226, - Dana Harris, Contract Specialist, Phone 301-594-9987, Fax 301-480-4226,
 

E-Mail Address

harrisd@extra.niddk.nih.gov, harrisd@extra.niddk.nih.gov
 

Description

The National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK) intends to negotiate on a sole source basis with the Jackson Laboratories (Bar Harbor, ME) to conduct a second phase of repository activity for animal models of Type 1 Diabetes and its complications. Jackson Labs is the one responsible source that can satisfy the Agency’s requirement because (1) Jackson Labs houses and maintains the archives of critical previously collected animal strains and data, (2) has extensive experience necessary to conduct activities proposed for the current contract; and (3) no other source can supply the services that will satisfy agency requirements for the follow-on work for this effort. Development of the original repository, the Type 1 Diabetes Repository at Jackson Labs (T1DR; http://www.jax.org/t1dr/index.html) was initiated in 2001 and supported by NIDDK through a supplement to an existing NCRR resource, the Induced Mutant Repository (IMR). Strain importation and associated studies and data collection were begun in 2001. To date, the T1DR has imported and archived nearly 150 strains important for diabetes research, and distributed over 500 mice to 100 independent investigators. In addition, disease incidence studies have been performed on nearly 20 of the imported recombinant strains within the context of Jackson Labs vivarium conditions. This ability to measure the impact of genetic changes on Type 1 Diabetes (T1D) within the context of the common and consistent environment provided within the Jackson Labs vivarium was a necessary and critical component of T1DR research activity in the prior project phase that must be maintained to provide consistency of results in Phase II. Finally, the ability of Jackson Laboratories to distribute T1DR-archived strains to investigators in most cases without the need for additional quarantine procedures beyond what is required for receipt of commercially available JAX strains is necessary to expedite and maximize the efficiency of research. For cost and efficiency purposes, NIDDK plans to continue the second phase of the T1DR using a single contractor (Jackson Laboratories). The contractor will continue activities to help identify mouse strains of unique value to T1D research, will import and archive these strains, will verify disease incidence and severity in a subset of the imported strains under controlled housing conditions, and will facilitate limited distribution of mice to the scientific community. In addition, the contractor will provide strain development support services for the NIDDK-funded Animal Models of Diabetic Complications Consortium. This activity will require production, housing, phenotyping, archiving, and distribution of mouse strains important for advancing research in diabetic complications. Pursuant to 41 U.S.C. 253(c)(1) as set forth in the Federal Acquisition Regulation (FAR) at 6.302-1, The Jackson Laboratories is the only source capable of performing this requirement due to their unique vivarium conditions and distribution capabilities, and prerequisite knowledge, experience and existing data generated through work performed under the prior supplement provided by NIDDK to the NCRR Induced Mutant Resource grant. To begin anew with a different source would result in substantial duplication of cost to the government that would not be recovered through competition, as well as unacceptable delays and loss of consistency in data describing disease incidence and severity. Interested parties may identify their interest and capability to respond to the requirements as described above. A determination not to compete the proposed work based upon responses to this notice is solely within the discretion of the Contracting Officer. This notice of intent is not an announcement of the availability of a Request for Proposal, nor is an RFP available. See Numbered Note 22. NOTE: THIS NOTICE MAY HAVE POSTED ON FEDBIZOPPS ON THE DATE INDICATED IN THE NOTICE ITSELF (03-MAY-2006). IT ACTUALLY APPEARED OR REAPPEARED ON THE FEDBIZOPPS SYSTEM ON 25-SEP-2006, BUT REAPPEARED IN THE FTP FEED FOR THIS POSTING DATE. PLEASE CONTACT fbo.support@gsa.gov REGARDING THIS ISSUE.
 

Web Link

Link to FedBizOpps document.
(http://www.fbo.gov/spg/HHS/NIH/NIDDKD/NIH-NIDDK-06-04/listing.html)
 

Place of Performance

Address: Bethesda, MD

Zip Code: 20817

Country: USA
 

Record

SN01154432-F 20060927/060925222912 (fbodaily.com)
 

Source

FedBizOpps Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |